Form 4: Immunome Director Sells Shares Under 10b5-1 Plan

Immunome Inc. Director Isaac Barchas reported the sale of common stock through a pre-arranged trading plan, with transactions occurring on July 6th and 7th, 2026.

Summary

• Director Isaac Barchas reported the sale of 83,094 shares of Immunome Inc. common stock on July 6, 2026, at a weighted average price of $24.11 per share. These shares were held indirectly through AMBHMC II LLC.
• An additional 16,906 shares were sold on July 7, 2026, at a weighted average price of $24.20 per share, also held indirectly through AMBHMC II LLC.
• These transactions were executed under a Rule 10b5-1 trading plan adopted by AMBHMC II LLC on March 31, 2026.
• Following these sales, Barchas beneficially owns 103,259 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine insider transactions executed under a pre-established trading plan, which is a common and regulated practice.

Negatives

• Director Isaac Barchas sold a significant number of shares (100,000 shares in total across two transactions).

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to insider transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan indicates a pre-planned strategy for stock sales, often used by executives and directors to diversify holdings or manage personal finances without violating insider trading regulations.

Stakeholder Impact

• Shareholders may note the sale of shares by a director, which could be interpreted in various ways, though the use of a 10b5-1 plan mitigates concerns about opportunistic trading.

Key Dates

Keywords

Immunome Inc., IMNM, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Director Transaction, Beneficial Ownership